Drug Profile

BMF 650

Alternative Names: BMF-650; GLP-1 receptor agonist - Biomea Fusion

Latest Information Update: 16 Oct 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biomea Fusion
Class Antihyperglycaemics; Obesity therapies; Small molecules
Mechanism of Action Glucagon-like peptide-1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Obesity
Preclinical Type 2 diabetes mellitus

Most Recent Events

14 Oct 2026 BMF 650 is available for licensing as of 14 Oct 2026. https://www.biomeafusion.com/
14 Oct 2026 Efficacy, pharmacokinetics and adverse events data from a phase I trial in obesity released by Biomea Fusion
26 Aug 2026 Biomea Fusion completes a phase I trial in Obesity (In volunteers) in USA (PO) (NCT07223216)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com